Ken Griffin Red Hill Biopharma Ltd. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$0.14 - $695.9 $1,652 - $8.21 Million
11,800 Added 27.63%
54,500 $7,000
Q3 2022

Nov 14, 2022
SELL
$0.5 - $523.8 $1,250 - $1.31 Million
-2,500 Reduced 5.53%
42,700 $21,000

Others Institutions Holding RDHL

# of Institutions
2
Shares Held
40.4K
Call Options Held
0
Put Options Held
0
View Full List

About RedHill Biopharma Ltd.

RDHL Quotes by TradingView
  • Ticker RDHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 63,823,500
  • Market Cap $465M
  • Description
  • RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...
More about RDHL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email